



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 353% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Other Revenues, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 196% points above the market average of 12%.

Input Variable	Value in 1000 USD
Assets, Current	431,173
Assets, Non-Current	2,592
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	35,182
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	33,349
Long Term Liabilities	1,172
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-233
Other Expenses	100,894
Other Liabilities	5,506
Other Net Income	4,430
Other Revenues	1,772
Property Plant and Equipment	1,326
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	435,091
Liabilities	40,027
Expenses	136,076
Revenues	1,772
Stockholders Equity	395,064
Net Income	-129,874
Comprehensive Net Income	-130,107
Economic Capital Ratio	208%